




TraumaShield: Protecting Minds Before Trauma Takes Hold.

The World's First Acute Neuro-Prophylaxis
for PTSD Prevention.



Trauma



Recovery ...

Trauma is Inevitable
PTSD is Preventable

Our mission is to make PTSD prevention the new global standard of care.
Converting a sensory nightmare into a historical narrative.

A Global Crisis of **Unhealed Minds**



70%

Of the world population
will experience traumatic
event in their life



13 Million+

Annual PTSD cases
in the US alone



\$232 Billion

Total annual economic
burden in the US



\$19,630

Annual cost per
affected individual (US)



Conversion Rate: 10-30% of trauma
survivors develop chronic PTSD



The Treatment Gap: Treating the Smoke, Not the Fire



Current treatments treat PTSD after the damage is done. No FDA-approved prevention exists for the “golden hours” post-trauma to disrupt fear memory consolidation.



The World's First PTSD Prevention Protocol.

A neurobiological intervention delivered in the immediate aftermath of trauma.



Immediate

Administered within the Golden Hour.



Proactive

Stops PTSD before it starts.




Scalable

Easy-to-use formulation.



The Mental Tourniquet

TraumaShield MDI System



Pre-filled Gas Delivery Chamber

Medical-grade barrier-layered PET.
2-Year Shelf Life.

Precision Flow-Limiting Valve

Controls delivery rate to match
respiratory rhythm.

Integrated Mask

Ergonomic seal for
rapid application.



Payload


Repurposed FDA-approved agent
prevents fear memory consolidation.

Key Specifications

- Single-Use & Disposable
- No Electricity Required
- Instant Activation
- Demographically
Optimized Dosing
(Child / Adult / Elderly)



Mechanism of Action: Modulating the Neural Storm




Result: The event is remembered as a historical narrative, not a relived sensory nightmare.



Clinical Validation & Proof of Concept


Human Data (Surgical Trauma Model).



Significant reduction in PTSD incidence at 1-month follow-up.

Preclinical Data (SEFL Models).

Stress-Enhanced Fear Learning (SEFL) significantly reduced in animal models.



Reduced fear response in treated animal models.


*p <0.05

*p <0.05

Data indicate efficacy in reducing PTSD development post-trauma.



A Multi-Billion Dollar Opportunity Driven by Recurring Revenue



50M Events × 20% Penetration
Price: \$300 / unit
=
SOM: \$3.0 BILLION



\$19,600 / yr
Chronic care cost

1:65 ROI



\$300
One-time intervention



B2P
(Insurers)

1:65
ROI

Value-Based
Care



B2B
(Hospitals)

Standard
of Care

Trauma Protocol
Integration



B2G
(Defense)

Stockpile
Essential

Munition-Grade
Pharma




Recurring Engine: 24-Month Expiry
Cycle | ~88.6% Gross Margin



Strategic Roadmap to commercialization(2025-2028)

Dual-track development leveraging 'Combination Product' regulatory advantages



Risk vs. Shield Matrix



Adoption Risk



Munition-Grade Design

Fits IFAK kits. [Zero training](#) required.



Clinical Risk



Repurposed Agent

Safety profile known. [47% reduction](#) in human data.



IP Risk



Method-of-Use Moat

[20-Year](#) Protection on [0-6hr](#) timing.



Regulatory Delays



505(b)(2) Pathway

Streamlined combination product approval.



Executive Leadership



David Slobodiansky

CEO

M.Sc. Neuroscience

**Business Strategy &
Project Management.**



Prof. Joseph Zohar

CMO

M.D.

**International Authority in
Psychiatry and Neuroscience.**

Backed by an on-site team of neuroscience experts,
psychiatrists, clinical and regulatory professionals.

Contact us:

David I TraumaShield

+972-542003244


daviddiner1@gmail.com

Changing the Trajectory of Trauma

- Massive Unmet Need
- Global Market Opportunity
- De-Risked Asset
- Preliminary data
- High-Barrier IP & Innovation



TraumaShield ...
PROTECTING MINDS BEFORE TRAUMA TAKES HOLD



JOIN US in Making TRAUMA a MEMORY, NOT a DISORDER